Elironrasib delivered a confirmed objective response rate of 42% (95% CI: 22–63) and a disease control rate of 79% (95% CI: 58–93) in 24 previously treated KRAS G12C non-small cell lung cancersmall cell lung cancerlung cancer patients, 92% of whom had progressed on a prior KRAS(OFF) G12C inhibitor. Median duration of response reached 11.2 months (95% CI: 5.9–not estimable), median progression-free survival was 6.2 months (95% CI: 4.0–10.3), and the 12-month overall survival rate was 62% (95% CI: 40–78), with median overall survival not yet reached. Patients received the recommended Phase 2 dose of 200 mg orally twice daily in the ongoing Phase 1 monotherapy study RMC-6291-001.
The update, presented at the AACR-NCI-EORTC Symposium, is the clearest signal to date that an RAS(ON) G12C-selective inhibitor can produce clinically meaningful activity after failure of KRAS(OFF) agents. While the company did not detail adverse event rates in this tranche, the dataset underscores momentum behind Revolution Medicines’ active-state RAS platform. Notably, elironrasib already holds FDA Breakthrough Therapy designation in a different setting—post-chemotherapy and immunotherapy, but before any KRAS G12C inhibitor—which gives the program a potential regulatory glidepath if the efficacy profile proves consistent across lines.
Strategically, Revolution is positioning elironrasib to solve a growing sequencing problem in KRAS-mutant NSCLC: resistance and cross-resistance after first-generation G12C inhibitors. Targeting RAS in its GTP-bound state is a clear differentiation against incumbent GDP-bound agents and against the field’s drift toward complex combinations that can add toxicity and operational friction. The company is also advancing a broader RAS(ON) portfolio, including a Phase 3 program (RASolve 301) for the multi-selective inhibitor daraxonrasib versus docetaxel and preclinical work on an in-pathway doublet, signaling an intention to own both monotherapy salvage and combination-first strategies across tumor types.
For trial operators and sites, this signal matters immediately. KRAS G12C testing is widely embedded in NSCLC workflows, and the post-KRAS inhibitor salvage population is expanding, making screening pipelines efficient. An oral BID regimen with radiographic response confirmation aligns with existing infrastructure, but the absence of granular safety data in this update means sites should anticipate forthcoming guidance on dose interruptions, lab monitoring, and discontinuation rates before scaling enrollment. For sponsors and CROs, the data open two potential registrational routes: a single-arm design in the post-KRAS inhibitor setting if the response rate and durability hold in a larger cohort, or a randomized study against docetaxel to future-proof regulatory acceptance as the bar for single-arm approvals continues to rise in lung cancer.
The competitive implications are nontrivial. If elironrasib reproduces a 40%+ response with median responses extending beyond 10 months in a post-G12C population, incumbent KRAS(OFF) players will face immediate pressure on life-cycle strategies and combination portfolios. Regulators will scrutinize durability, OS trends, and the consistency of benefit across resistance genotypes, while payers will look for clean enrollment criteria and manageable tox profiles. Operationally, the platform’s breadth suggests potential for cross-program site activation, but it also risks internal prioritization trade-offs if overlapping indications compete for the same patients.
What to watch next: expansion cohort size and maturation of safety data, especially grade 3/4 events and discontinuations; updated PFS/OS at 12–18 months; clarity on a registrational plan in the post-KRAS inhibitor setting and whether FDA will accept a high-quality single-arm package; biomarker analyses that might guide sequencing after KRAS(OFF) agents; and read-through from daraxonrasib’s Phase 3 to the broader regulatory posture on active-state RAS inhibition. The near-term question is whether elironrasib can convert a promising mechanism into a scalable, regulator-ready salvage option in a crowded KRAS market.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
